Veteran biotech entrepreneur Harvey Berger, who has been on the sidelines for the past five years, is returning to the fray as chief executive of venture-based Boston startup Kojin Therapeutics.
The company, founded in 2019 by a scientific team that includes Harvard research professor Stuart Schreiber, is developing classes of pills that employ ferroptosis biology to attack a wide range of diseases.
Over the past decade, scientists have begun understanding the role played by ferroptosis, an iron-dependent form of cell death, in a variety of illnesses. Kojin, which has about 15 employees working in the Seaport district, is developing a class of pills that can induce ferroptosis to kill cancer cells and another class that can block ferroptosis to prevent neurogenerative diseases. The company hasn’t yet disclosed its lead drug candidates.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.statnews.com/2024/01/03/harvey-berger-kojin-therapeutics/?utm_campaign=rss